Day 1, 6:47 AM. I swallowed the first Foundayo pill with black coffee and a slice of cold pizza from the fridge. Not the healthiest breakfast, but I needed a baseline that reflected reality, not Instagram. Eli Lilly's orforglipron — branded Foundayo, approved April 2026, the first non-peptide small-molecule oral GLP-1 receptor agonist — had arrived at my pharmacy on East 7th Street the night before. I had a spreadsheet open before I even swallowed. Weight: 187.4 lbs. BMI: 26.8. Fasting glucose: 94 mg/dL. Blood pressure: 118/76. Mood: cautiously annoyed that I was doing this again.
I should explain why I am a sample size of one. I am not a doctor. I am a former data analyst who used to build dashboards for fintech stock prices and now builds dashboards for his own body. I lost 35 pounds not by following a diet but by following the data. When Foundayo hit the market, I knew I had to treat myself like a Phase 3 trial participant. n=1. The weakest statistical power in science. But the most honest.
Here is what the data says about Foundayo before I even started. The ATTAIN-1 trial followed 3,127 adults over 72 weeks. Mean weight loss was 11.2% on the middle dose, with more than half of participants achieving at least 10% reduction. The highest dose showed 12.4% average weight loss — about 27 pounds. That is less than Wegovy's 14.9% and far less than Zepbound's 20.9%. But Foundayo is a pill. Once daily. No injection. No refrigeration. No needles. The adherence curve for oral medications is historically 20-30% better than injectables over 12 months. That is not a small detail. That is the difference between a drug that works in trials and a drug that works in real life.
Calculate your BMI instantly with visual category charts and history storage.
All data stays in your browser — we never see it.Week 1 was chaos. I started on the 12 mg dose, the standard titration starting point. Nausea hit on day 3. Not the dramatic projectile kind you see in TikTok videos, but a persistent, low-grade queasiness that made my usual breakfast taco from Veracruz All Natural feel like a betrayal. I logged it. Nausea severity: 4/10. Duration: 6 hours. Trigger: solid food before 10 AM. By day 5, I had shifted to smoothies and protein shakes before noon. The nausea dropped to 2/10. I was already optimizing. Old data analyst habits die hard.
Weight on day 7: 185.9 lbs. Down 1.5 pounds. Mostly water, probably. I know the difference between fat loss and glycogen depletion. But the number went down, and I am human enough to feel a small, irrational surge of validation. Pixel looked at me with that judgmental expression she reserves for people who check the scale too often. I checked it again anyway.
Week 2 was the adjustment phase. My appetite suppression kicked in around day 10. Not the dramatic "I never want to eat again" feeling some people describe with semaglutide. More like a subtle dimmer switch on hunger. I would look at the H-E-B prepared meals I had been eating for convenience and think, "I could eat that, or I could just have an apple." The apple won more often than not. I tracked my daily calories using a rough estimate method. Baseline pre-Foundayo: 2,400 calories per day. Week 2 average: 1,680. That is a 30% reduction without conscious restriction. The drug was doing the work my willpower had never managed.
Estimate body fat percentage using the US Navy tape method and BMI-based formulas.
All data stays in your browser — we never see it.By week 3, I had settled into a rhythm. Morning pill with coffee. Light breakfast at 10 AM. Main meal at 2 PM. Snack at 7 PM. Sleep by 11. My Oura ring — yes, I switched to a smart ring for this experiment, more on that later — showed my sleep latency improving from 28 minutes to 19 minutes. HRV went from 42 ms to 51 ms. I do not know if that is the drug or the reduced late-night snacking or both. Correlation is not causation. But the trend lines are pretty.
Week 4 was the first real test. SXSW may be over, but Austin in late April is still festival season. I went to a friend's birthday at a bar on Rainey Street. Tacos. Margaritas. The kind of night that normally derails any diet. I took my Foundayo that morning. I ate two tacos instead of four. I had one margarita instead of three. I was not white-knuckling it. I genuinely did not want more. The drug had rewired my satiety signal. I felt like a cyborg with better firmware.
End of week 4 weight: 180.2 lbs. Down 7.2 pounds in 28 days. BMI dropped from 26.8 to 25.7. I crossed the overweight-to-normal threshold on day 26. I took a screenshot of the scale and sent it to my friend Sarah, the one who actually knows things. She replied: "Jamie, that is water and glycogen. Wait for week 8." She was right, of course. But I kept the screenshot.
Calculate your daily calorie needs with TDEE and activity level adjustments.
All data stays in your browser — we never see it.Weeks 5 through 8 were the plateau watch. Every weight loss curve has a flattening phase. I hit mine at day 34. Weight: 179.8. Day 35: 179.6. Day 36: 180.1. I stared at the spreadsheet like it had personally betrayed me. I increased my step count from 8,000 to 12,000 per day. I started doing rucking again on the Butler Trail with my YVO Warrior group. The weight started moving again on day 41. By the end of week 8, I was at 177.4 lbs. Total loss: 10 pounds. That is 5.3% of my starting weight. The ATTAIN-1 trial showed 11.2% at 72 weeks. I am on track for the lower end of the curve, which makes sense for a middle dose and a non-obese starting BMI.
Side effects by week 8: nausea is gone. Constipation is real. I added psyllium husk to my morning routine and it resolved within three days. I had one episode of mild hypoglycemia on day 52 — shaky hands, sweating, ate a banana, felt fine in 20 minutes. I logged it. Blood glucose at the time: 68 mg/dL. That is low but not dangerous. I have not had a recurrence.
Cost analysis: Foundayo list price is $1,049 per month. My insurance covers it with a $75 copay. Without insurance, the LillyDirect cash price is $499 for the first month, then $749 ongoing. Compare to Wegovy at $1,349 list and roughly $1,000 cash. The oral pill is cheaper. But here is the data point that matters: adherence. I have not missed a single dose in 30 days. When I tried Wegovy last year, I missed two injections because of travel and fridge logistics. Pills travel better. Pills do not need ice packs. Pills fit in a pocket. The real-world efficacy gap between oral and injectable may be smaller than the trial data suggests, simply because more people actually take the pill.
So here is my 30-day verdict. Foundayo works. Not as dramatically as the injectables. Not as fast as the headlines promise. But it works consistently, conveniently, and with manageable side effects. My BMI went from 26.8 to 25.3. My fasting glucose dropped from 94 to 82. My daily calorie intake fell by 30% without misery. I am not a success story. I am a spreadsheet with a pulse. And the spreadsheet says this drug is worth watching.
Would I stay on it? At $75 per month, yes. At $1,049, no. The Medicare GLP-1 Bridge program covers Foundayo at $50 for eligible seniors, which is going to change the market dynamics entirely. For someone like me — 38, self-employed, buying insurance on the marketplace — the cost-benefit is marginal. For a 65-year-old with BMI 30 and hypertension, it is a no-brainer. The data is clear. The distribution is messy. And that, my friends, is why I keep the spreadsheet open.
